[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 22 of about 22
1. Kitagami H, Kondo S, Hirano S, Kawakami H, Egawa S, Tanaka M: Acinar cell carcinoma of the pancreas: clinical analysis of 115 patients from Pancreatic Cancer Registry of Japan Pancreas Society. Pancreas; 2007 Jul;35(1):42-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: The present study investigated the clinical characteristics, treatment, and therapeutic outcomes of 115 patients registered in the Pancreatic Cancer Registry of the Japan Pancreas Society, and therapeutic plans were reviewed.
  • If ACC is unresectable or recurrent, chemotherapy is likely to prove useful.
  • Multidisciplinary therapy centering on the role of surgery will need to be established.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor. Female. Humans. Japan / epidemiology. Male. Middle Aged. Neoplasm Staging / statistics & numerical data. Prognosis. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17575544.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


2. Moran E, Masters S, Berendt AR, McLardy-Smith P, Byren I, Atkins BL: Guiding empirical antibiotic therapy in orthopaedics: The microbiology of prosthetic joint infection managed by debridement, irrigation and prosthesis retention. J Infect; 2007 Jul;55(1):1-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Guiding empirical antibiotic therapy in orthopaedics: The microbiology of prosthetic joint infection managed by debridement, irrigation and prosthesis retention.
  • OBJECTIVES: This study describes the microbiological spectrum of prosthetic joint infection (PJI) managed by debridement, washout and retention and so guides the choice of empirical antibiotics within this patient group.
  • METHODS: We performed a retrospective review of all patients admitted to our specialist tertiary unit for PJI who were managed with debridement and irrigation or arthroscopic washout of infected prosthetic joints between 1st January 1998 and 30th April 2003.
  • Eighty-six percent of polymicrobial cultures occurred in early infections when 47% of patients grew more than one organism.
  • MSSA was the most frequently isolated organism at all time points.
  • CONCLUSIONS: Most infections involved staphylococci.
  • Most polymicrobial infections occurred in early infection.
  • A high rate of resistance to cephalosporins among Gram-negative organisms justifies the use of a broader agent such as a carbapenem in the early empirical antibiotic regime for PJI.
  • [MeSH-major] Anti-Bacterial Agents. Arthroplasty, Replacement / adverse effects. Gram-Negative Bacteria / drug effects. Joint Prosthesis / adverse effects. Prosthesis-Related Infections / drug therapy. Staphylococcus / drug effects
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Debridement. Female. Gram-Negative Bacterial Infections / drug therapy. Gram-Negative Bacterial Infections / microbiology. Hip Prosthesis / adverse effects. Humans. Knee Prosthesis / adverse effects. Male. Microbial Sensitivity Tests. Middle Aged. Staphylococcal Infections / microbiology. Staphylococcus aureus / drug effects. Staphylococcus aureus / isolation & purification. Therapeutic Irrigation

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17343916.001).
  • [ISSN] 1532-2742
  • [Journal-full-title] The Journal of infection
  • [ISO-abbreviation] J. Infect.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents
  •  go-up   go-down


3. Saeki H, Sugimasa Y, Yamada R, Akaike M, Takemiya S, Masaki T, Miyagawa K, Okawa S: [Intraoperative radiotherapy (IORT) for unresectable stage IVb pancreatic cancer]. Gan To Kagaku Ryoho; 2002 Nov;29(12):2221-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Twelve patients were treated with IORT, 17 with external beam radiotherapy (ERT) and 17 with chemotherapy (CHT, 8 patients doxorubicin-based, 7 patients 5-FU-based).
  • [MeSH-minor] Combined Modality Therapy. Female. Humans. Intraoperative Care. Male. Middle Aged. Neoplasm Metastasis. Quality of Life. Survival Rate

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12484041.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


Advertisement
4. Sieroń A, Hese RT, Sobiś J, Cieślar G: [Estimation of therapeutical efficacy of weak variable magnetic fields with low value of induction in patients with depression]. Psychiatr Pol; 2004 Mar-Apr;38(2):217-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM: Preliminary results of research on the therapeutical efficacy of weak variable magnetic fields with low value of induction used as magnetostimulation in patients with depression not reacting to two consecutive, correctly applied anti-depressant pharmacological treatment are presented in the paper.
  • In 1 group (11 persons--9 women and 2 men) magnetostimulation with the use of a weak variable magnetic field with a low value of induction of 15 microT generated by the VIOFOR JPS device (Poland) lasting 12 minutes daily for 15 days was added to pharmacological therapy.
  • CONCLUSIONS: It was concluded that adding magnetostimulation to pharmacological therapy results in a progressive, significant reduction of intensification of depression symptoms.
  • [MeSH-major] Antidepressive Agents, Second-Generation / administration & dosage. Depressive Disorder / physiopathology. Depressive Disorder / therapy. Magnetics / therapeutic use
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Electromagnetic Fields. Female. Fluvoxamine / administration & dosage. Humans. Male. Middle Aged. Paroxetine / administration & dosage. Severity of Illness Index. Surveys and Questionnaires. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Depression.
  • Hazardous Substances Data Bank. PAROXETINE HYDROCHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15307288.001).
  • [ISSN] 0033-2674
  • [Journal-full-title] Psychiatria polska
  • [ISO-abbreviation] Psychiatr. Pol.
  • [Language] pol
  • [Publication-type] Clinical Trial; English Abstract; Journal Article; Randomized Controlled Trial
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antidepressive Agents, Second-Generation; 41VRH5220H / Paroxetine; O4L1XPO44W / Fluvoxamine
  •  go-up   go-down


5. Shimoyama M: [Guideline for phase I study on new anticancer agents]. Gan To Kagaku Ryoho; 2001 Feb;28(2):261-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Since more than 50% of patients with cancer could no be cured by present standard therapy, new effective anticancer agents are needed in clinical level.
  • This paper shows major parts of a report entitled "Guideline for phase I study on new anticancer agents", already published in JPs Pharmacol Ther 26: 441-454, 1998, with minor modification in order to answer these issues.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Clinical Trials, Phase I as Topic / standards
  • [MeSH-minor] Humans. Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11242659.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


6. Tani M, Kawai M, Terasawa H, Ina S, Hirono S, Uchiyama K, Yamaue H: Does postoperative chemotherapy have a survival benefit for patients with pancreatic cancer? J Surg Oncol; 2006 May 1;93(6):485-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does postoperative chemotherapy have a survival benefit for patients with pancreatic cancer?
  • In our study, we investigated whether postoperative chemotherapy improved survival in patients with invasive ductal carcinoma of the pancreas.
  • Median survival time (MST) was 19.4 months, 8.6 months, and 7.2 months, in JPS Stage III (UICC Stage IIA and IIB), JPS Stage IVa (UICC Stage IIA and IIB), and JPS Stage IVb (UICC Stage IV), respectively (P < 0.01).
  • The MST of the chemotherapy group was 12 months, and the MST of the non-chemotherapy group was 8.4 months (P < 0.05).
  • Moreover, in JPS Stage IV (UICC Stage IIA, IIB, III, and IV) highly advanced pancreatic cancer, the MST of the chemotherapy group was 10.9 months, and the MST of the group without chemotherapy was 6.6 months (P < 0.01).
  • Since pancreatic cancer is characterized by an aggressive tumor with a high recurrent rate, postoperative chemotherapy is effective for an improvement of survival.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Pancreatic Ductal / drug therapy. Pancreatectomy / mortality. Pancreatic Neoplasms / drug therapy
  • [MeSH-minor] Aged. Combined Modality Therapy. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Female. Fluorouracil / administration & dosage. Humans. Infusions, Intra-Arterial. Male. Middle Aged. Neoplasm Staging. Postoperative Care. Survival Rate

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • (PMID = 16615151.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


7. Dong Z, Zhou L, Del Villar K, Ghanevati M, Tashjian V, Miller CA: JIP1 regulates neuronal apoptosis in response to stress. Brain Res Mol Brain Res; 2005 Apr 4;134(2):282-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thus, under certain stress conditions, down-regulation of JIP1 expression makes neurons more susceptible to apoptosis, suggesting JIP may serve as an anti-apoptosis factor.
  • [MeSH-minor] Animals. Animals, Newborn. Anoxia / drug therapy. Anoxia / metabolism. Blotting, Western / methods. Caspase 3. Caspases / metabolism. Cell Line, Tumor. Cell Survival / drug effects. Enzyme Inhibitors / pharmacology. Hippocampus / cytology. Humans. Immunohistochemistry / methods. Indoles. MAP Kinase Kinase 7 / metabolism. Mice. Mitogen-Activated Protein Kinase 10 / metabolism. Neuroblastoma. Organ Culture Techniques. Proto-Oncogene Proteins c-jun / metabolism. Rats. Rats, Sprague-Dawley. Time Factors. Transfection / methods. Ultraviolet Rays / adverse effects

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15836924.001).
  • [ISSN] 0169-328X
  • [Journal-full-title] Brain research. Molecular brain research
  • [ISO-abbreviation] Brain Res. Mol. Brain Res.
  • [Language] eng
  • [Grant] United States / NIMH NIH HHS / MH / 5R37MH39145; United States / NINDS NIH HHS / NS / 5T32NS07149; United States / NIA NIH HHS / AG / AG05142; United States / NIA NIH HHS / AG / AG18879
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Enzyme Inhibitors; 0 / Indoles; 0 / MAPK8IP1 protein, human; 0 / Proto-Oncogene Proteins c-jun; 47165-04-8 / DAPI; EC 2.7.1.- / MAP2K7 protein, human; EC 2.7.1.- / Mitogen-Activated Protein Kinase 10; EC 2.7.12.2 / MAP Kinase Kinase 7; EC 3.4.22.- / CASP3 protein, human; EC 3.4.22.- / Casp3 protein, mouse; EC 3.4.22.- / Casp3 protein, rat; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspases
  •  go-up   go-down


8. You JH, Lee GC, So RK, Cheung KW, Hui M: Linezolid versus vancomycin for prosthetic joint infections: a cost analysis. Infection; 2007 Jun;35(4):265-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Linezolid versus vancomycin for prosthetic joint infections: a cost analysis.
  • BACKGROUND: Prosthetic joint infections (PJIs) caused by methicillin-resistant gram-positive bacteria are primarily treated by intravenous vancomycin.
  • Linezolid, active against methicillin-resistant strains and available in oral and intravenous dosage forms, is a potential alternative to vancomycin for the treatment of PJIs.
  • OBJECTIVE: To analyze the cost of linezolid therapy (outpatient setting) and vancomycin therapy (inpatient and outpatient settings) for PJIs caused by methicillin-resistant gram-positive bacteria.
  • METHODS: A decision tree was designed to simulate the clinical outcome and healthcare resource utilization of linezolid, vancomycin by outpatient and home parenteral antimicrobial therapies (OHPAT) and vancomycin administered in inpatient setting (rehabilitation facility) for patients with PJIs caused by methicillin-resistant strains.
  • The clinical treatment success rates of vancomycin and linezolid were influential factors.
  • Monte Carlo 10,000 simulations showed that the vancomycin (OHPAT) group was less costly than the arms of linezolid and vancomycin (rehabilitation) 64% and 100% of the time, respectively.
  • The linezolid group was less costly than the vancomycin (rehabilitation) group in 65%of the times.
  • CONCLUSION: Home-infusion of vancomycin therapy appears to be the least costly treatment approach for PJIs caused by methicillin-resistant gram-positive bacteria from the perspective of a Hong Kong public health organization.
  • [MeSH-major] Acetamides. Anti-Bacterial Agents. Health Care Costs / statistics & numerical data. Oxazolidinones. Prosthesis-Related Infections. Vancomycin
  • [MeSH-minor] Administration, Oral. Algorithms. Costs and Cost Analysis. Gram-Positive Bacterial Infections / drug therapy. Gram-Positive Bacterial Infections / economics. Home Care Services / economics. Humans. Infusions, Intravenous / economics. Joint Prosthesis / microbiology. Linezolid. Methicillin Resistance / genetics

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • Hazardous Substances Data Bank. Vancomycin .
  • Hazardous Substances Data Bank. LINEZOLID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17646907.001).
  • [ISSN] 0300-8126
  • [Journal-full-title] Infection
  • [ISO-abbreviation] Infection
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Acetamides; 0 / Anti-Bacterial Agents; 0 / Oxazolidinones; 6Q205EH1VU / Vancomycin; ISQ9I6J12J / Linezolid
  •  go-up   go-down


9. Half E, Bercovich D, Rozen P: Familial adenomatous polyposis. Orphanet J Rare Dis; 2009;4:22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Familial adenomatous polyposis.
  • Familial adenomatous polyposis (FAP) is characterized by the development of many tens to thousands of adenomas in the rectum and colon during the second decade of life.
  • Generally, cancers start to develop a decade after the appearance of the polyps.
  • A less aggressive variant of FAP, attenuated FAP (AFAP), is characterized by fewer colorectal adenomatous polyps (usually 10 to 100), later age of adenoma appearance and a lower cancer risk.
  • Classic FAP is inherited in an autosomal dominant manner and results from a germline mutation in the adenomatous polyposis (APC) gene.
  • Most patients (~70%) have a family history of colorectal polyps and cancer.
  • In a subset of individuals, a MUTYH mutation causes a recessively inherited polyposis condition, MUTYH-associated polyposis (MAP), which is characterized by a slightly increased risk of developing CRC and polyps/adenomas in both the upper and lower gastrointestinal tract.
  • Differential diagnoses include other disorders causing multiple polyps (such as Peutz-Jeghers syndrome, familial juvenile polyps or hyperplastic polyposis, hereditary mixed polyposis syndromes, and Lynch syndrome).
  • Patients with progressive tumors and unresectable disease may respond or stabilize with a combination of cytotoxic chemotherapy and surgery (when possible to perform).
  • Adjunctive therapy with celecoxib has been approved by the US Food and Drug Administration and the European Medicines Agency in patients with FAP.
  • Individuals with FAP carry a 100% risk of CRC; however, this risk is reduced significantly when patients enter a screening-treatment program.
  • [MeSH-major] Adenomatous Polyposis Coli / diagnosis. Adenomatous Polyposis Coli / pathology

  • Genetic Alliance. consumer health - Familial Adenomatous Polyposis (FAP).
  • Genetic Alliance. consumer health - Familial Polyposis.
  • SciCrunch. KEGG: Data: Disease Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Gastroenterol. 1993 Dec;17(4):343-7, discussion 347-8 [8308223.001]
  • [Cites] Hum Mutat. 1994;3(2):121-5 [8199592.001]
  • [Cites] Hum Genet. 1994 Nov;94(5):543-8 [7959691.001]
  • [Cites] N Engl J Med. 1995 Mar 30;332(13):839-47 [7661930.001]
  • [Cites] Ann Surg. 1995 Aug;222(2):120-7 [7639579.001]
  • [Cites] Am Fam Physician. 1995 Sep 15;52(4):1210 [7668210.001]
  • [Cites] Surgery. 1996 Jun;119(6):615-23 [8650601.001]
  • [Cites] Br J Surg. 1996 Jun;83(6):769-70 [8696735.001]
  • [Cites] Br J Surg. 1996 Jul;83(7):885-92 [8813770.001]
  • [Cites] J Med Genet. 1996 Jul;33(7):540-3 [8818937.001]
  • [Cites] Br J Surg. 1996 Nov;83(11):1578-80 [9014679.001]
  • [Cites] AJR Am J Roentgenol. 1997 Aug;169(2):465-72 [9242755.001]
  • [Cites] Ann Surg. 1997 Oct;226(4):514-9; discussion 519-21 [9351719.001]
  • [Cites] Arch Dis Child. 1997 Nov;77(5):431-5 [9487968.001]
  • [Cites] Am J Hum Genet. 1998 Mar;62(3):736-7 [9497250.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Apr;8(4 Pt 2):353-60 [10207640.001]
  • [Cites] Am J Hum Genet. 1999 Sep;65(3):902-9 [10441594.001]
  • [Cites] Nucleic Acids Res. 1999 Sep 15;27(18):3638-44 [10471731.001]
  • [Cites] Fam Cancer. 2006;5(3):213-20 [16998666.001]
  • [Cites] Fam Cancer. 2006;5(3):227-35 [16998668.001]
  • [Cites] Fam Cancer. 2006;5(3):241-60; discussion 261-2 [16998670.001]
  • [Cites] Fam Cancer. 2006;5(3):275-85; discussion 287-8 [16998673.001]
  • [Cites] Gastrointest Endosc. 2006 Oct;64(4):530-7 [16996344.001]
  • [Cites] Genet Med. 2006 Nov;8(11):697-703 [17108761.001]
  • [Cites] Reprod Biomed Online. 2006 Nov;13(5):707-11 [17169185.001]
  • [Cites] Mol Hum Reprod. 2007 Feb;13(2):95-101 [17114207.001]
  • [Cites] Am J Gastroenterol. 2007 Jun;102(6):1284-90 [17355417.001]
  • [Cites] Hum Mutat. 2007 Oct;28(10):985-92 [17486639.001]
  • [Cites] Genet Test. 2007 Fall;11(3):315-20 [17949294.001]
  • [Cites] Gastrointest Endosc. 2008 Jan;67(1):61-7 [18155426.001]
  • [Cites] Clin Gastroenterol Hepatol. 2008 Feb;6(2):180-5 [18237868.001]
  • [Cites] Fam Cancer. 2008;7(1):27-39 [17999161.001]
  • [Cites] Gut. 2008 May;57(5):704-13 [18194984.001]
  • [Cites] Curr Protoc Hum Genet. 2006 Aug;Chapter 10:Unit 10.8 [18428386.001]
  • [Cites] Endoscopy. 2008 May;40(5):437-42 [18398783.001]
  • [Cites] Am J Surg. 2008 Jun;195(6):741-8 [18436175.001]
  • [Cites] Clin Chem. 2008 Jul;54(7):1132-40 [18487285.001]
  • [Cites] Pathol Res Pract. 2008;204(7):479-90 [18538487.001]
  • [Cites] Ann Surg Oncol. 2008 Sep;15(9):2439-50 [18612695.001]
  • [Cites] Eur J Cancer. 2008 Nov;44(16):2404-10 [18706807.001]
  • [Cites] Gastrointest Endosc. 2008 Nov;68(5):911-9 [18561922.001]
  • [Cites] Gastroenterology. 2008 Dec;135(6):2014-8 [19013464.001]
  • [Cites] J Pediatr. 1999 Sep;135(3):390-5 [10484811.001]
  • [Cites] Endoscopy. 1999 Aug;31(6):412-6 [10494676.001]
  • [Cites] Am J Hum Genet. 1955 Sep;7(3):236-63 [13258558.001]
  • [Cites] Dis Colon Rectum. 1959 Sep-Oct;2:465-8 [13839882.001]
  • [Cites] Genet Test. 2004 Winter;8(4):421-30 [15684875.001]
  • [Cites] N Engl J Med. 2005 Mar 17;352(11):1092-102 [15713943.001]
  • [Cites] Am J Med Genet A. 2005 Apr 15;134A(2):212-4 [15690400.001]
  • [Cites] Gastroenterology. 2005 Apr;128(4):1077-80 [15825088.001]
  • [Cites] Am J Gastroenterol. 2005 Jul;100(7):1498-502 [15984971.001]
  • [Cites] Dis Colon Rectum. 2005 Aug;48(8):1528-34 [15906134.001]
  • [Cites] Biochem Soc Trans. 2005 Aug;33(Pt 4):679-83 [16042573.001]
  • [Cites] Am J Med Genet A. 2006 Feb 1;140(3):200-4 [16411234.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Feb;15(2):312-4 [16492921.001]
  • [Cites] Br J Surg. 2006 Apr;93(4):407-17 [16511903.001]
  • [Cites] Int J Cancer. 2006 Aug 15;119(4):807-14 [16557584.001]
  • [Cites] Gut. 1999 Dec;45(6):829-33 [10562580.001]
  • [Cites] Nucleic Acids Res. 2000 Mar 15;28(6):1355-64 [10684930.001]
  • [Cites] J Clin Oncol. 2000 May;18(9):1967-79 [10784639.001]
  • [Cites] N Engl J Med. 2000 Jun 29;342(26):1946-52 [10874062.001]
  • [Cites] Dis Colon Rectum. 2000 Jul;43(7):893-8; discussion 898-902 [10910233.001]
  • [Cites] Am J Pathol. 2000 Sep;157(3):747-54 [10980114.001]
  • [Cites] Gastroenterology. 2000 Dec;119(6):1454-60 [11113066.001]
  • [Cites] Ann Surg. 2001 Mar;233(3):360-4 [11224623.001]
  • [Cites] Arch Ophthalmol. 2001 Apr;119(4):597-602 [11296028.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 May 1;50(1):121-5 [11316554.001]
  • [Cites] Gastroenterology. 2001 Jul;121(1):195-7 [11438508.001]
  • [Cites] J Wound Ostomy Continence Nurs. 2001 Jul;28(4):184-9 [11452254.001]
  • [Cites] Nat Genet. 2002 Feb;30(2):227-32 [11818965.001]
  • [Cites] Gastroenterology. 2002 Mar;122(3):641-5 [11874996.001]
  • [Cites] N Engl J Med. 2002 Apr 4;346(14):1054-9 [11932472.001]
  • [Cites] Gut. 2002 May;50(5):636-41 [11950808.001]
  • [Cites] J Gastrointest Surg. 2002 Jan-Feb;6(1):82-7 [11986022.001]
  • [Cites] Hum Mutat. 2002 Jun;19(6):664 [12007223.001]
  • [Cites] Gut. 2002 Sep;51(3):446-9 [12171972.001]
  • [Cites] J Clin Microbiol. 2002 Oct;40(10):3565-71 [12354847.001]
  • [Cites] Dis Colon Rectum. 2002 Nov;45(11):1496-502 [12432298.001]
  • [Cites] Br J Surg. 2003 Feb;90(2):227-31 [12555301.001]
  • [Cites] N Engl J Med. 2003 Feb 27;348(9):791-9 [12606733.001]
  • [Cites] Dis Colon Rectum. 2003 Apr;46(4):481-5 [12682541.001]
  • [Cites] Cancer Res. 2003 Apr 15;63(8):1752-5 [12702556.001]
  • [Cites] Gastroenterology. 2003 May;124(6):1574-94 [12761718.001]
  • [Cites] Cancer Res. 2003 Jul 15;63(14):3891-3 [12873979.001]
  • [Cites] Dis Colon Rectum. 2003 Oct;46(10):1418-23; discussion 1422-3 [14530685.001]
  • [Cites] Fam Cancer. 2001;1(2):75-82 [14574001.001]
  • [Cites] Fam Cancer. 2003;2(1):43-55 [14574166.001]
  • [Cites] Clin Cancer Res. 2003 Oct 15;9(13):4756-60 [14581346.001]
  • [Cites] Dig Dis Sci. 2003 Oct;48(10):1998-2002 [14627347.001]
  • [Cites] Genet Test. 2003 Fall;7(3):189-94 [14641994.001]
  • [Cites] Cancer. 2004 Feb 1;100(3):612-20 [14745880.001]
  • [Cites] Gut. 2004 Mar;53(3):381-6 [14960520.001]
  • [Cites] Hum Mutat. 2003 Jun;21(6):655-6 [14961559.001]
  • [Cites] Int J Cancer. 2004 May 1;109(5):680-4 [14999774.001]
  • [Cites] Oncogene. 2004 Sep 2;23(40):6820-2 [15273732.001]
  • [Cites] Gastroenterology. 2004 Sep;127(3):838-44 [15362039.001]
  • [Cites] Acta Chir Scand. 1975;141(3):228-37 [1166747.001]
  • [Cites] Am J Hum Genet. 1988 Feb;42(2):290-6 [3422541.001]
  • [Cites] Lancet. 1989 Sep 30;2(8666):783-5 [2571019.001]
  • [Cites] Ann Med. 1989 Aug;21(4):299-307 [2551351.001]
  • [Cites] Gastroenterology. 1991 Jun;100(6):1658-64 [1673441.001]
  • [Cites] Cell. 1991 Aug 9;66(3):589-600 [1651174.001]
  • [Cites] Science. 1991 Aug 9;253(5020):665-9 [1651563.001]
  • [Cites] Nature. 1992 Sep 17;359(6392):235-7 [1528264.001]
  • [Cites] N Engl J Med. 1993 May 6;328(18):1313-6 [8385741.001]
  • [Cites] Am J Hum Genet. 1993 Jul;53(1):33-45 [8317496.001]
  • (PMID = 19822006.001).
  • [ISSN] 1750-1172
  • [Journal-full-title] Orphanet journal of rare diseases
  • [ISO-abbreviation] Orphanet J Rare Dis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 114
  • [Other-IDs] NLM/ PMC2772987
  •  go-up   go-down


10. Hellmark B, Unemo M, Nilsdotter-Augustinsson A, Söderquist B: Antibiotic susceptibility among Staphylococcus epidermidis isolated from prosthetic joint infections with special focus on rifampicin and variability of the rpoB gene. Clin Microbiol Infect; 2009 Mar;15(3):238-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antibiotic susceptibility among Staphylococcus epidermidis isolated from prosthetic joint infections with special focus on rifampicin and variability of the rpoB gene.
  • Staphylococcus epidermidis is the most important pathogen in infections related to implanted foreign materials, especially prosthetic joint infections (PJIs).
  • The aim of this study was to investigate the antimicrobial activities of 16 antibiotics against S. epidermidis isolated from PJIs, with special focus on rifampicin and rpoB variability.
  • Among the other antibiotics, the rates of resistance varied between 0% (vancomycin) and 82% (trimethoprim-sulphamethoxazole). S. epidermidis strains causing PJIs often show multiresistance, including resistance to rifampicin, which is mainly caused by one or two SNPs.
  • Some of the newer antimicrobial agents may provide alternatives for monotherapy or combination therapy with rifampicin.
  • Detection of mecA is necessary before initiating treatment of infections due to S. epidermidis when it displays intermediate susceptibility to cefoxitin.
  • [MeSH-major] Anti-Bacterial Agents / pharmacology. DNA-Directed RNA Polymerases / genetics. Drug Resistance, Bacterial. Prosthesis-Related Infections / microbiology. Rifampin / pharmacology. Staphylococcal Infections / microbiology. Staphylococcus epidermidis / drug effects
  • [MeSH-minor] Humans. Joint Prosthesis / adverse effects. Microbial Sensitivity Tests / methods

  • MedlinePlus Health Information. consumer health - Antibiotic Resistance.
  • MedlinePlus Health Information. consumer health - Antibiotics.
  • MedlinePlus Health Information. consumer health - Staphylococcal Infections.
  • Hazardous Substances Data Bank. RIFAMPIN .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19196261.001).
  • [ISSN] 1469-0691
  • [Journal-full-title] Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
  • [ISO-abbreviation] Clin. Microbiol. Infect.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; EC 2.7.7.6 / DNA-Directed RNA Polymerases; EC 2.7.7.6 / RNA polymerase beta subunit; VJT6J7R4TR / Rifampin
  •  go-up   go-down


11. Rao N, Regalla DM: Uncertain efficacy of daptomycin for prosthetic joint infections: a prospective case series. Clin Orthop Relat Res; 2006 Oct;451:34-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Uncertain efficacy of daptomycin for prosthetic joint infections: a prospective case series.
  • Daptomycin is an option for prosthetic joint infection (PJI) because it is bactericidal against gram-positive bacteria, including multiple-resistant isolates, and active against stationary-phase bacteria in biofilm present on implants.
  • To evaluate its possible utility, we prospectively monitored 12 adults with gram-positive PJI who were not candidates for vancomycin.
  • One died of an unrelated cause shortly after completing therapy.
  • Five patients had culture-confirmed failure-all due to MRSA-including two during therapy despite hardware removal and three 1 to 10 months after completing daptomycin but with retained hardware.
  • The efficacy of daptomycin 4 mg/kg/day is uncertain in patients with PJI, especially when hardware is retained.
  • [MeSH-major] Anti-Bacterial Agents / therapeutic use. Arthroplasty, Replacement / adverse effects. Daptomycin / therapeutic use. Joint Prosthesis / adverse effects. Prosthesis-Related Infections / drug therapy. Staphylococcal Infections / drug therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Drug Administration Schedule. Feasibility Studies. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • MedlinePlus Health Information. consumer health - Staphylococcal Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16735866.001).
  • [ISSN] 0009-921X
  • [Journal-full-title] Clinical orthopaedics and related research
  • [ISO-abbreviation] Clin. Orthop. Relat. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; NWQ5N31VKK / Daptomycin
  •  go-up   go-down


12. Stebbins JL, De SK, Machleidt T, Becattini B, Vazquez J, Kuntzen C, Chen LH, Cellitti JF, Riel-Mehan M, Emdadi A, Solinas G, Karin M, Pellecchia M: Identification of a new JNK inhibitor targeting the JNK-JIP interaction site. Proc Natl Acad Sci U S A; 2008 Oct 28;105(43):16809-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of a new JNK inhibitor targeting the JNK-JIP interaction site.
  • In animal studies, BI-78D3 not only blocks JNK dependent Con A-induced liver damage but also restores insulin sensitivity in mouse models of type 2 diabetes.
  • In view of its favorable inhibition profile, selectivity, and ability to function in the cellular milieu and in vivo, BI-78D3 represents not only a JNK inhibitor, but also a promising stepping stone toward the development of an innovative class of therapeutics.

  • BindingDB. BindingDB .
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 1999 Nov 1;18(45):6158-62 [10557107.001]
  • [Cites] Diabetes. 2001 Jan;50(1):77-82 [11147798.001]
  • [Cites] J Biol Chem. 2002 Mar 29;277(13):10987-97 [11790767.001]
  • [Cites] Nat Rev Drug Discov. 2003 Jul;2(7):554-65 [12815381.001]
  • [Cites] Curr Opin Pharmacol. 2003 Aug;3(4):420-5 [12901952.001]
  • [Cites] J Biol Chem. 2003 Aug 29;278(35):32662-72 [12788955.001]
  • [Cites] Immunity. 2003 Nov;19(5):725-37 [14614859.001]
  • [Cites] EMBO J. 2004 Jun 2;23(11):2185-95 [15141161.001]
  • [Cites] Nat Med. 2004 Oct;10(10):1128-32 [15448687.001]
  • [Cites] Drug News Perspect. 2004 Sep;17(7):447-53 [15514704.001]
  • [Cites] J Biol Chem. 1990 Oct 5;265(28):17355-63 [2170374.001]
  • [Cites] Cell. 1994 Mar 25;76(6):1025-37 [8137421.001]
  • [Cites] J Mol Graph. 1994 Jun;12(2):98-105 [7918258.001]
  • [Cites] Genes Dev. 1994 Dec 15;8(24):2996-3007 [8001819.001]
  • [Cites] EMBO J. 1996 Jun 3;15(11):2760-70 [8654373.001]
  • [Cites] Brain Res Mol Brain Res. 1996 Jan;35(1-2):47-57 [8717339.001]
  • [Cites] J Mol Med (Berl). 1996 Oct;74(10):589-607 [8912180.001]
  • [Cites] Cell. 1996 Nov 29;87(5):929-39 [8945519.001]
  • [Cites] J Mol Biol. 1997 Apr 4;267(3):727-48 [9126849.001]
  • [Cites] Science. 1997 Aug 1;277(5326):693-6 [9235893.001]
  • [Cites] J Comput Aided Mol Des. 1997 Sep;11(5):425-45 [9385547.001]
  • [Cites] Biochim Biophys Acta. 1997 Oct 24;1333(2):F85-104 [9395283.001]
  • [Cites] EMBO J. 1998 Mar 16;17(6):1740-9 [9501095.001]
  • [Cites] Curr Opin Cell Biol. 1998 Apr;10(2):205-19 [9561845.001]
  • [Cites] Science. 1998 Sep 11;281(5383):1671-4 [9733513.001]
  • [Cites] Adv Drug Deliv Rev. 2005 Feb 28;57(4):609-36 [15722167.001]
  • [Cites] J Biol Chem. 2006 Jun 2;281(22):15258-67 [16571730.001]
  • [Cites] Anal Biochem. 2008 Jan 15;372(2):189-97 [17961489.001]
  • [Cites] Curr Mol Med. 2007 Nov;7(7):674-86 [18045145.001]
  • [Cites] J Med Chem. 2008 Jun 26;51(12):3460-5 [18494454.001]
  • [CommentIn] Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):E18; author reply E19 [19204298.001]
  • (PMID = 18922779.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R21 DK073274; United States / NIDDK NIH HHS / DK / R24 DK080263; United States / NIDDK NIH HHS / DK / R21DK073274; United States / NIDDK NIH HHS / DK / R24DK080263
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 4-(2,3-dihydro-1,4-benzodioxin-6-yl)-2,4-dihydro-5-((5-nitro-2-thiazolyl)thio)-3H-1,2,4-triazol-3-one; 0 / Adaptor Proteins, Signal Transducing; 0 / Dioxanes; 0 / MAPK8IP1 protein, human; 0 / Protein Kinase Inhibitors; 0 / Thiazoles; EC 2.7.11.24 / JNK Mitogen-Activated Protein Kinases
  • [Other-IDs] NLM/ PMC2567907
  •  go-up   go-down


13. Schäfer P, Fink B, Sandow D, Margull A, Berger I, Frommelt L: Prolonged bacterial culture to identify late periprosthetic joint infection: a promising strategy. Clin Infect Dis; 2008 Dec 1;47(11):1403-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prolonged bacterial culture to identify late periprosthetic joint infection: a promising strategy.
  • BACKGROUND: The value of microbiological culture to diagnose late periprosthetic infection is limited, especially because standard methods may fail to detect biofilm-forming sessile or other fastidious bacteria.
  • This study was designed to assess the duration of culture that is necessary for reliable detection.
  • PATIENTS AND METHODS: Ten periprosthetic tissue specimens each were obtained during revision from 284 patients with suspected late hip or knee arthroplasty infection.
  • To define infection, a pre-established algorithm was used; this included detection of indistinguishable organisms in >/=2 tissue samples or growth in 1 tissue sample and a positive result of histologic analysis (>5 neutrophils in at least 10 high-power fields).
  • The time to detection of organisms was monitored.
  • RESULTS: Infection was diagnosed in 110 patients.
  • After 7 days (the longest incubation period most frequently reported), the detection rate via culture was merely 73.6%.
  • Organisms indicating infection were found for up to 13 days.
  • In both populations, an unequivocal correlation between the number of culture-positive tissue samples and positive results of histologic analysis was noted, which corroborated the evidence that true infections were detected over the entire cultivation period.
  • CONCLUSIONS: Prolonged microbiological culture for 2 weeks is promising because it yields signs of periprosthetic infection in a significant proportion of patients that would otherwise remain unidentified.
  • [MeSH-major] Arthritis / diagnosis. Bacterial Infections / diagnosis. Bacteriological Techniques. Hip / microbiology. Knee / microbiology. Prosthesis-Related Infections / diagnosis
  • [MeSH-minor] Aged. Bacteria / isolation & purification. Female. Humans. Male. Statistics as Topic. Time Factors


14. Matsuno S, Egawa S, Fukuyama S, Motoi F, Sunamura M, Isaji S, Imaizumi T, Okada S, Kato H, Suda K, Nakao A, Hiraoka T, Hosotani R, Takeda K: Pancreatic Cancer Registry in Japan: 20 years of experience. Pancreas; 2004 Apr;28(3):219-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Preoperative histologic diagnosis and diagnostic imaging are fundamentals in managing the disease, but it is not rare to find unexpected peritoneal dissemination or liver metastasis at the time of operation.
  • Multidisciplinary treatments combined with surgery were performed, and various effects of postoperative chemotherapy after pancreatectomy, intraoperative- and postoperative-radiation therapy, or postoperative chemotherapy for unresectable tumor, were shown.
  • Development of unconventional therapies and refinement of the conventional therapy should be promoted on a randomized prospective trial basis.
  • To promote this effort, which requires the international comparisons and cooperation, JPS developed a computerized JPS registration system downloadable from the JPS website (http://www.kojin.or.jp/suizou/index.html).
  • [MeSH-major] Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / therapy. Registries
  • [MeSH-minor] Adenocarcinoma / pathology. Adult. Aged. Combined Modality Therapy. Female. Humans. Japan. Lymph Node Excision. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Pancreatectomy. Prognosis. Survival Analysis


15. Frampton JE, Keating GM: Celecoxib: a review of its use in the management of arthritis and acute pain. Drugs; 2007;67(16):2433-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is approved in one or more countries worldwide for the relief of the signs and symptoms of osteoarthritis (OA), rheumatoid arthritis (RA), juvenile rheumatoid arthritis (in patients aged > or =2 years) and ankylosing spondylitis (AS), the management of acute pain in adults, the treatment of primary dysmenorrhoea and the reduction in the number of adenomatous colorectal polyps in familial adenomatous polyposis.
  • Celecoxib remains an effective and useful altenative to nonselective NSAIDs in the treatment of acute or chronic musculoskeletal pain.
  • In the latter setting, it offers the prospect of improved gastrointestinal (GI) tolerability and, in patients not taking aspirin for cardioprophylaxis, a GI safety advantage.
  • As with all NSAIDs, the potential GI, CV and renal risks of celecoxib must be weighed against the potential benefits in each individual; it is a rational choice for patients at low CV risk who require NSAID therapy, especially those at increased risk of NSAID-induced GI toxicity, but also those unresponsive to, or intolerant of, other NSAIDs.
  • [MeSH-major] Arthritis / drug therapy. Cyclooxygenase 2 Inhibitors / therapeutic use. Pain / drug therapy. Pyrazoles / therapeutic use. Sulfonamides / therapeutic use

  • Genetic Alliance. consumer health - Arthritis.
  • MedlinePlus Health Information. consumer health - Arthritis.
  • MedlinePlus Health Information. consumer health - Pain.
  • Hazardous Substances Data Bank. CELECOXIB .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] BMJ. 2002 Sep 21;325(7365):619 [12242171.001]
  • [Cites] J Int Med Res. 2003 Mar-Apr;31(2):102-12 [12760313.001]
  • [Cites] Anesth Analg. 2007 Jul;105(1):228-32 [17578979.001]
  • [Cites] Arthritis Rheum. 2007 Jun 15;57(5):748-55 [17530673.001]
  • [Cites] Pharmacotherapy. 2001 Oct;21(10):1223-32 [11601668.001]
  • [Cites] Rheumatology (Oxford). 2007 Mar;46(3):496-507 [16936327.001]
  • [Cites] Pharmacotherapy. 1999 Nov;19(11):1269-78 [10555933.001]
  • [Cites] BMC Gastroenterol. 2007 Jul 04;7:25 [17610716.001]
  • [Cites] Pharmacotherapy. 2005 Apr;25(4):503-10 [15977911.001]
  • [Cites] Curr Med Res Opin. 2001;17(3):210-6 [11900314.001]
  • [Cites] Pharmacoepidemiol Drug Saf. 2006 Sep;15(9):641-52 [16392153.001]
  • [Cites] Curr Med Res Opin. 2007 Jan;23(1):163-73 [17257477.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 Sep;4(9):1082-9 [16877048.001]
  • [Cites] BMJ. 2003 Dec 6;327(7427):1322-3 [14656840.001]
  • [Cites] Br J Anaesth. 2001 Jul;87(1):73-87 [11460815.001]
  • [Cites] Drugs. 2000 Apr;59(4):957-80 [10804043.001]
  • [Cites] Ann Intern Med. 2005 Apr 5;142(7):481-9 [15809459.001]
  • [Cites] N Engl J Med. 2005 Mar 17;352(11):1092-102 [15713943.001]
  • [Cites] Ann Allergy Asthma Immunol. 2004 Oct;93(4):360-4 [15521372.001]
  • [Cites] Clin Rheumatol. 2006 Nov;25(6):778-81 [16609823.001]
  • [Cites] N Engl J Med. 2006 Feb 23;354(8):795-808 [16495392.001]
  • [Cites] Pharmacol Rep. 2005;57 Suppl:66-85 [16415488.001]
  • [Cites] Clin Ther. 2001 Feb;23(2):228-41 [11293556.001]
  • [Cites] Clin Ther. 2002 Dec;24(12 ):2051-63 [12581544.001]
  • [Cites] Br J Clin Pharmacol. 2002 Sep;54(3):327-32 [12236854.001]
  • [Cites] Am J Cardiol. 2007 Jan 1;99(1):91-8 [17196469.001]
  • [Cites] Arthritis Rheum. 2002 Feb;46(2):328-46 [11840435.001]
  • [Cites] Clin Ther. 2002 Oct;24(10):1549-60 [12462285.001]
  • [Cites] J Rheumatol Suppl. 2006 Sep;78:4-11 [17042055.001]
  • [Cites] Scand J Rheumatol. 2004;33(1):1-6 [15124935.001]
  • [Cites] JAMA. 2000 Sep 13;284(10):1247-55 [10979111.001]
  • [Cites] Curr Opin Anaesthesiol. 2007 Oct;20(5):440-50 [17873597.001]
  • [Cites] J Rheumatol. 2004 Aug;31(8):1614-20 [15290743.001]
  • [Cites] N Engl J Med. 2005 Mar 17;352(11):1081-91 [15713945.001]
  • [Cites] Clin J Sport Med. 2004 Jul;14(4):225-31 [15273528.001]
  • [Cites] Can J Anaesth. 2007 May;54(5):342-8 [17470884.001]
  • [Cites] Arthritis Rheum. 2003 Nov;48(11):3102-11 [14613272.001]
  • [Cites] Br J Clin Pharmacol. 2006 Sep;62(3):358-65 [16934052.001]
  • [Cites] J Pain. 2000 Sep;1(3 Suppl):14-8 [14622838.001]
  • [Cites] Clin Ther. 1999 Oct;21(10):1653-63 [10566562.001]
  • [Cites] Arthroscopy. 2006 Jul;22(7):804 [16843817.001]
  • [Cites] Nat Rev Drug Discov. 2003 Nov;2(11):879-90 [14668809.001]
  • [Cites] Curr Pharm Des. 2004;10(6):589-601 [14965322.001]
  • [Cites] Expert Opin Drug Saf. 2005 Nov;4(6):1005-15 [16255660.001]
  • [Cites] Ann Rheum Dis. 2008 Mar;67(3):323-9 [17616556.001]
  • [Cites] Ann Rheum Dis. 2003 Dec;62(12):1145-55 [14644851.001]
  • [Cites] Arch Intern Med. 2002 May 27;162(10):1099-104 [12020178.001]
  • [Cites] BMJ. 2006 Jun 3;332(7553):1302-8 [16740558.001]
  • [Cites] Ann Rheum Dis. 2007 Mar;66(3):377-88 [17046965.001]
  • [Cites] BMJ. 2005 Dec 3;331(7528):1310-6 [16322018.001]
  • [Cites] Aliment Pharmacol Ther. 2006 Sep 15;24(6):897-908 [16948802.001]
  • [Cites] Ann Rheum Dis. 2007 Sep;66(9):1178-83 [17363401.001]
  • [Cites] Am J Ther. 2007 Jan-Feb;14(1):3-12 [17303969.001]
  • [Cites] Arch Intern Med. 2005 Jan 24;165(2):189-92 [15668365.001]
  • [Cites] Ann Pharmacother. 2007 Jun;41(6):937-43 [17488830.001]
  • [Cites] Hypertension. 2002 Apr;39(4):929-34 [11967252.001]
  • [Cites] Am J Hypertens. 2003 Feb;16(2):135-9 [12559680.001]
  • [Cites] Lancet. 2004 May 29;363(9423):1751-6 [15172772.001]
  • [Cites] Manag Care Interface. 2003 Oct;16(10):38-45 [14606259.001]
  • [Cites] Am J Ther. 2001 Mar-Apr;8(2):85-95 [11304662.001]
  • [Cites] Arthritis Care Res. 2000 Apr;13(2):112-21 [14635284.001]
  • [Cites] Am J Cardiol. 2002 Mar 21;89(6A):18D-25D [11909557.001]
  • [Cites] Am J Cardiol. 2002 Feb 15;89(4):425-30 [11835924.001]
  • [Cites] Rheumatology (Oxford). 2004 May;43(5):592-5 [14762227.001]
  • [Cites] Clin Rheumatol. 2006;25 Suppl 1:S22-9 [16741783.001]
  • [Cites] J Physiol Pharmacol. 2006 Nov;57 Suppl 5:113-24 [17218763.001]
  • [Cites] N Engl J Med. 2006 Aug 31;355(9):885-95 [16943401.001]
  • [Cites] Am J Med. 2005 Nov;118(11):1271-8 [16271912.001]
  • [Cites] Ann Rheum Dis. 2004 Aug;63(8):931-9 [15082468.001]
  • [Cites] Lancet. 2007 May 12;369(9573):1580-1 [17499583.001]
  • [Cites] J Clin Pharmacol. 2002 Aug;42(8):912-9 [12162474.001]
  • [Cites] Curr Med Res Opin. 2006 Jan;22(1):199-210 [16393445.001]
  • [Cites] J Rheumatol. 2006 Sep;33(9):1805-12 [16960941.001]
  • [Cites] Clin Drug Investig. 2004;24(2):89-101 [17516695.001]
  • [Cites] Lancet. 2007 May 12;369(9573):1621-6 [17499604.001]
  • [Cites] Circulation. 2006 Sep 5;114(10):1028-35 [16943394.001]
  • [Cites] Circulation. 2004 May 4;109(17):2068-73 [15096449.001]
  • [Cites] N Engl J Med. 2006 Aug 31;355(9):873-84 [16943400.001]
  • [Cites] Arthritis Res Ther. 2005;7(3):R644-65 [15899051.001]
  • [Cites] Clin Gastroenterol Hepatol. 2007 Oct;5(10):1167-74 [17916545.001]
  • [Cites] Singapore Med J. 2006 Jun;47(6):534-42 [16752024.001]
  • [Cites] Curr Top Med Chem. 2007;7(3):235-49 [17305567.001]
  • [Cites] Am J Ther. 2000 May;7(3):153-8 [11317164.001]
  • [Cites] BMJ. 2002 Sep 21;325(7365):624 [12242172.001]
  • [Cites] Circulation. 2003 Sep 9;108(10):1191-5 [12939216.001]
  • [Cites] Gut. 2006 Dec;55(12):1731-8 [16687434.001]
  • [Cites] JAMA. 2002 Jan 2;287(1):64-71 [11754710.001]
  • [Cites] Arthritis Rheum. 2006 Nov;54(11):3390-8 [17075817.001]
  • [Cites] J Clin Rheumatol. 2000 Apr;6(2):65-74 [19078452.001]
  • [Cites] PLoS Clin Trials. 2006 Nov 17;1(7):e33 [17111043.001]
  • [Cites] J Rheumatol. 2004 Jun;31(6):1143-51 [15170928.001]
  • [Cites] Arthritis Rheum. 2005 Jun;52(6):1756-65 [15934081.001]
  • [Cites] Clin Ther. 1999 Sep;21(9):1497-513; discussion 1427-8 [10509845.001]
  • [Cites] Stroke. 2003 Feb;34(2):379-86 [12574546.001]
  • [Cites] Am J Ther. 2000 May;7(3):159-75 [11317165.001]
  • [Cites] Arch Intern Med. 2005 May 9;165(9):978-84 [15883235.001]
  • [Cites] J R Soc Med. 2006 Mar;99(3):132-40 [16508052.001]
  • [Cites] Ann Rheum Dis. 2007 Jan;66(1):34-45 [16396980.001]
  • [Cites] Hypertension. 2003 Sep;42(3):310-5 [12874094.001]
  • [Cites] Lancet. 2003 Feb 15;361(9357):573-4 [12598144.001]
  • [Cites] Clin Pharmacokinet. 2000 Mar;38(3):225-42 [10749518.001]
  • [Cites] Lancet. 1999 Dec 18-25;354(9196):2106-11 [10609815.001]
  • [Cites] Circulation. 2004 Jun 22;109(24):3000-6 [15197149.001]
  • [Cites] J Clin Pharmacol. 2000 Jun;40(6):655-63 [10868317.001]
  • [Cites] Lancet. 2002 Oct 5;360(9339):1071-3 [12383990.001]
  • [Cites] J Am Coll Cardiol. 2004 Mar 17;43(6):985-90 [15028354.001]
  • [Cites] J Clin Pharmacol. 2000 Feb;40(2):124-32 [10664917.001]
  • [Cites] J Clin Rheumatol. 2001 Jun;7(3):151-9 [17039120.001]
  • [Cites] Am J Ther. 2003 Jan-Feb;10(1):12-20 [12522515.001]
  • [Cites] Arthritis Rheum. 2007 Apr 15;57(3):516-23 [17394181.001]
  • [Cites] Acta Anaesthesiol Scand. 2004 May;48(5):525-46 [15101847.001]
  • [Cites] FASEB J. 2004 May;18(7):790-804 [15117884.001]
  • [Cites] Arthritis Rheum. 2002 Aug;46(8):2201-6 [12209526.001]
  • [Cites] J Clin Pharmacol. 2002 Sep;42(9):1027-30 [12211219.001]
  • [Cites] Am J Med. 2006 Mar;119(3):255-66 [16490472.001]
  • [Cites] Ann Rheum Dis. 2005 May;64(5):669-81 [15471891.001]
  • [Cites] JAMA. 2006 Oct 4;296(13):1633-44 [16968831.001]
  • [Cites] Ann Pharmacother. 2001 Jul-Aug;35(7-8):829-34 [11485128.001]
  • [Cites] Osteoarthritis Cartilage. 2007 Sep;15(9):981-1000 [17719803.001]
  • [Cites] Biomed Chromatogr. 2002 Feb;16(1):56-60 [11816012.001]
  • [Cites] Circulation. 2003 Jan 28;107(3):405-9 [12551863.001]
  • [Cites] Curr Opin Rheumatol. 2006 May;18(3):221-6 [16582683.001]
  • [Cites] J Rheumatol. 2004 Feb;31(2):355-8 [14760808.001]
  • [Cites] Ann Intern Med. 2005 Feb 1;142(3):157-64 [15684203.001]
  • [Cites] Drugs. 2001;61(8):1133-41; discussion 1142-3 [11465874.001]
  • [Cites] Epidemiology. 2000 Jul;11(4):382-7 [10874543.001]
  • [Cites] Arthritis Rheum. 2000 Jan;43(1):4-13 [10643694.001]
  • [Cites] Expert Opin Drug Saf. 2006 Jan;5(1):83-94 [16370958.001]
  • [Cites] Trials. 2007 Apr 11;8:13 [17428328.001]
  • [Cites] CMAJ. 2002 Nov 12;167(10):1131-7 [12427705.001]
  • [Cites] Clin Rheumatol. 2006 Feb;25(1):42-53 [16132165.001]
  • [Cites] Circulation. 2007 Mar 27;115(12):1634-42 [17325246.001]
  • [Cites] J Am Coll Cardiol. 2007 Jan 2;49(1):1-14 [17207715.001]
  • [Cites] Basic Clin Pharmacol Toxicol. 2006 Mar;98(3):266-74 [16611201.001]
  • [Cites] J Pain Palliat Care Pharmacother. 2006;20(4):11-32 [17182503.001]
  • [Cites] J Pain Palliat Care Pharmacother. 2005;19(4):83-97 [16431839.001]
  • [Cites] Am J Cardiol. 2002 Mar 21;89(6A):10D-17D [11909556.001]
  • [Cites] Scand J Rheumatol. 2001;30(1):11-8 [11252686.001]
  • [Cites] Am J Cardiol. 2002 Nov 1;90(9):959-63 [12398962.001]
  • [Cites] Hypertension. 2004 Aug;44(2):140-5 [15226279.001]
  • [Cites] Circulation. 2006 Jun 27;113(25):2906-13 [16785336.001]
  • [Cites] Clin Ther. 1999 Dec;21(12):2065-79 [10645754.001]
  • [Cites] BMC Musculoskelet Disord. 2007 Aug 03;8:73 [17683540.001]
  • [Cites] Arthroscopy. 2006 Jun;22(6):635-42 [16762702.001]
  • [Cites] Pharmacoepidemiol Drug Saf. 2007 May;16(5):493-503 [17086567.001]
  • [Cites] ACP J Club. 2005 Jul-Aug;143(1):2 [15989290.001]
  • [Cites] Curr Med Res Opin. 2005 Apr;21(4):517-26 [15899100.001]
  • [Cites] Rheumatology (Oxford). 2003 Nov;42 Suppl 3:iii17-22 [14585914.001]
  • [Cites] JAMA. 2001 Nov 21;286(19):2398; author reply 2399-400 [11712924.001]
  • [Cites] Am J Kidney Dis. 2001 Dec;38(6):1145-57 [11728945.001]
  • [Cites] JAMA. 1999 Nov 24;282(20):1921-8 [10580457.001]
  • [Cites] Arch Intern Med. 2002 May 27;162(10):1105-10 [12020179.001]
  • [Cites] Arthritis Rheum. 2001 Jan;44(1):180-5 [11212158.001]
  • [Cites] J Gerontol A Biol Sci Med Sci. 2001 Mar;56(3):M167-75 [11253158.001]
  • [Cites] Lancet. 2004 Aug 21-27;364(9435):665-74 [15325831.001]
  • [Cites] Am J Cardiol. 2003 Aug 15;92(4):411-8 [12914871.001]
  • [Cites] Ann Allergy Asthma Immunol. 2005 Aug;95(2):154-8 [16136765.001]
  • [Cites] Ann Rheum Dis. 2006 Apr;65(4):442-52 [16126791.001]
  • [Cites] Arthritis Rheum. 2000 Sep;43(9):1905-15 [11014340.001]
  • [Cites] Arch Intern Med. 2005 Mar 14;165(5):490-6 [15710786.001]
  • [Cites] J Int Med Res. 2001 Nov-Dec;29(6):467-79 [11803730.001]
  • [Cites] Clin Ther. 2001 Feb;23(2):213-27 [11293555.001]
  • [Cites] Presse Med. 2006 Sep;35(9 Spec No 1):1S11-23 [17078591.001]
  • [Cites] J Bone Joint Surg Am. 2005 Mar;87(3):536-42 [15741619.001]
  • [Cites] Clin Ther. 2005 Jan;27(1):64-77 [15763607.001]
  • [Cites] Mayo Clin Proc. 1999 Nov;74(11):1095-105 [10560596.001]
  • [Cites] N Engl J Med. 2002 Dec 26;347(26):2104-10 [12501222.001]
  • [Cites] Lancet. 2002 Jan 12;359(9301):118-23 [11809254.001]
  • [Cites] Swiss Med Wkly. 2006 Oct 28;136(43-44):684-90 [17183430.001]
  • [Cites] N Engl J Med. 2001 Aug 9;345(6):433-42 [11496855.001]
  • [Cites] Pharmacoepidemiol Drug Saf. 2004 May;13(5):277-87 [15133778.001]
  • [Cites] Am J Orthop (Belle Mead NJ). 2002 Aug;31(8):445-51 [12216965.001]
  • [Cites] Drug Saf. 2003;26(3):187-95 [12580647.001]
  • [Cites] N Engl J Med. 2005 Mar 17;352(11):1071-80 [15713944.001]
  • [Cites] J Clin Pharmacol. 2005 Jul;45(7):751-62 [15951465.001]
  • [Cites] Arch Intern Med. 2005 Jan 24;165(2):161-8 [15668361.001]
  • [Cites] Circulation. 2006 Apr 25;113(16):1950-7 [16618816.001]
  • [Cites] Ann Rheum Dis. 2007 Jan;66(1):99-106 [16815864.001]
  • [Cites] Rheumatology (Oxford). 2007 Mar;46(3):435-8 [17255138.001]
  • [Cites] N Engl J Med. 2000 Nov 23;343 (21):1520-8, 2 p following 1528 [11087881.001]
  • [Cites] Arch Intern Med. 2003 Feb 24;163(4):481-6 [12588209.001]
  • [Cites] Drug Saf. 2001;24(4):239-47 [11330653.001]
  • [Cites] Eur Heart J. 2006 Jul;27(14):1657-63 [16731535.001]
  • [Cites] J Rheumatol. 2005 Jun;32(6):1093-105 [15940774.001]
  • [Cites] Gastroenterology. 2004 Oct;127(4):1256-8 [15481002.001]
  • [Cites] Pharmacoepidemiol Drug Saf. 2007 Jul;16(7):762-72 [17457957.001]
  • [Cites] Lancet. 2005 Feb 5-11;365(9458):475-81 [15705456.001]
  • [Cites] Ann Rheum Dis. 2004 Nov;63(11):1419-26 [15020310.001]
  • (PMID = 17983259.001).
  • [ISSN] 0012-6667
  • [Journal-full-title] Drugs
  • [ISO-abbreviation] Drugs
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Cyclooxygenase 2 Inhibitors; 0 / Pyrazoles; 0 / Sulfonamides; JCX84Q7J1L / Celecoxib
  • [Number-of-references] 219
  •  go-up   go-down


16. Motycka V, Sákra L, Mencl K, Havlícek K: [Occurrence of yeast infections at a surgical intensive care unit]. Rozhl Chir; 2001 Jun;80(6):320-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Occurrence of yeast infections at a surgical intensive care unit].
  • [Transliterated title] Výskyt kvasinkových infekcí na chirurgické JIP.
  • The authors evaluate the occurrence of candida infections in the surgical intensive care unit (ICU) in a one-year period.
  • From the group of 1798 patients hospitalized in a surgical ICU there are 50 patients (2.8%) with candida colonisation and even 56 patients (3.1%) with candida infection.
  • The authors evaluate risk factors for development of candida infection, its etiologic agents and the most frequent site of infection.
  • In addition to usual treatment the authors suggest pre-emptive therapy in patients with risk factors.
  • In the one-year period, two patients died of multiorgan failure (MOF) in close connection with candida infection (sepsis).
  • The mortality of the group with proved candida infection was 3.57%.
  • [MeSH-major] Candidiasis. Cross Infection
  • [MeSH-minor] Humans. Intensive Care Units. Mycoses / diagnosis. Mycoses / drug therapy. Mycoses / transmission. Retrospective Studies. Risk Factors. Trichosporon

  • MedlinePlus Health Information. consumer health - Yeast Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11482157.001).
  • [ISSN] 0035-9351
  • [Journal-full-title] Rozhledy v chirurgii : měsíčník Československé chirurgické společnosti
  • [ISO-abbreviation] Rozhl Chir
  • [Language] cze
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


17. Kuan CY, Burke RE: Targeting the JNK signaling pathway for stroke and Parkinson's diseases therapy. Curr Drug Targets CNS Neurol Disord; 2005 Feb;4(1):63-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeting the JNK signaling pathway for stroke and Parkinson's diseases therapy.
  • This unique property makes JNK signaling a promising target for developing pharmacological intervention.
  • The inhibitors of the JNK signaling pathway include upstream kinase inhibitors (for example, CEP-1347), small chemical inhibitors of JNK (SP600125 and AS601245), and peptide inhibitors of the interaction between JNK and its substrates (D-JNKI and I-JIP).
  • [MeSH-minor] Alzheimer Disease / drug therapy. Alzheimer Disease / enzymology. Animals. Cell Death / drug effects. Cell Death / physiology. Drug Design. Humans

  • MedlinePlus Health Information. consumer health - Parkinson's Disease.
  • MedlinePlus Health Information. consumer health - Stroke.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15723614.001).
  • [ISSN] 1568-007X
  • [Journal-full-title] Current drug targets. CNS and neurological disorders
  • [ISO-abbreviation] Curr Drug Targets CNS Neurol Disord
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; EC 2.7.11.24 / JNK Mitogen-Activated Protein Kinases
  • [Number-of-references] 46
  •  go-up   go-down


18. Sobiś J, Jarzab M, Hese RT, Sieroń A, Zyss T, Gorczyca P, Gierlotka Z, Pudlo R, Matysiakiewicz J: Therapeutic efficacy assessment of weak variable magnetic fields with low value of induction in patients with drug-resistant depression. J Affect Disord; 2010 Jun;123(1-3):321-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapeutic efficacy assessment of weak variable magnetic fields with low value of induction in patients with drug-resistant depression.
  • BACKGROUND: The aim of this prospective study was to verify whether magnetostimulation with weak variable magnetic fields with low value of induction could enhance the effects of pharmacological therapy in drug-resistant depression.
  • MATERIALS AND METHODS: Thirty patients, 26 women and 4 men, with drug-resistant depression were enrolled in the study.
  • I (14 patients) were given fluvoxamine and treated with weak variable magnetic field using the VIOFOR JPS device; the subjects from Group No.
  • II (16 patients) were also given fluvoxamine but they were treated with the VIOFOR JPS device in placebo mode.
  • RESULTS: After 15 days of treatment highly significant differences were revealed between the patients treated with magnetic field and the patients treated with placebo: the final HDRS score was 53% of the initial value for the group receiving combined treatment, and 86% in the placebo group (p<0.001); for MADRS score the values were 51% and 88% (p<0.001), respectively, and for BDI 60% and 87% (p<0.001).
  • 15% reduction of symptoms, while the concurrent application of magnetic field and SSRI treatment resulted in a 40-50% improvement.
  • CONCLUSION: Our study indicates that adding a two-week low-induction variable magnetic field stimulation to a classical pharmacologic therapy reduces the intensity of symptoms in patients with drug-resistant depressive disorders.
  • [MeSH-major] Antidepressive Agents, Second-Generation / therapeutic use. Depressive Disorder, Major / therapy. Fluvoxamine / therapeutic use. Transcranial Magnetic Stimulation / methods
  • [MeSH-minor] Adult. Combined Modality Therapy. Dose-Response Relationship, Drug. Drug Administration Schedule. Drug Resistance. Female. Humans. Male. Middle Aged. Personality Inventory. Prospective Studies

  • Genetic Alliance. consumer health - Depression.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier B.V. All rights reserved.
  • (PMID = 19896204.001).
  • [ISSN] 1573-2517
  • [Journal-full-title] Journal of affective disorders
  • [ISO-abbreviation] J Affect Disord
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antidepressive Agents, Second-Generation; O4L1XPO44W / Fluvoxamine
  •  go-up   go-down


19. Doi R, Kami K, Ito D, Kawaguchi Y, Uemoto S, Yoshida S: [Surgical treatment of carcinoma of the pancreas]. Nihon Geka Gakkai Zasshi; 2006 Jul;107(4):168-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical treatment of carcinoma of the pancreas].
  • Invasive ductal carcinoma of the pancreas (pancreatic cancer) is mainly treated by operative resection, radio-chemotherapy, or chemotherapy.
  • The survival rate of the patients with each treatment is not good when compared with that in other cancers.
  • In addition, the volume of pancreatic cancer patients treated at the institution and the surgeon's personal experience may greatly affect the decision.
  • A recent randomized clinical trial from Japan revealed that surgical resection has a survival advantage over chemo-radiation therapy for locally advanced pancreatic cancer, which is defined as stage IVa in the fourth Japanese edition of the Classification of Pancreatic Carcinoma.
  • In addition, the surgical indications should be reevaluated in combination with the adjuvant or neoadjuvant chemotherapy in future.
  • [MeSH-minor] Combined Modality Therapy. Humans. Neoplasm Staging. Practice Guidelines as Topic. Randomized Controlled Trials as Topic. Survival Rate

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16878408.001).
  • [ISSN] 0301-4894
  • [Journal-full-title] Nihon Geka Gakkai zasshi
  • [ISO-abbreviation] Nihon Geka Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 7
  •  go-up   go-down


20. Estes CS, Beauchamp CP, Clarke HD, Spangehl MJ: A two-stage retention débridement protocol for acute periprosthetic joint infections. Clin Orthop Relat Res; 2010 Aug;468(8):2029-38
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A two-stage retention débridement protocol for acute periprosthetic joint infections.
  • BACKGROUND: Due to the historically poor infection control rates with débridement and component retention for acute periprosthetic infections we developed a new approach for treating acute periprosthetic total joint infections: initial débridement with prosthesis retention and placement of antibiotic-impregnated cement beads followed by a second débridement within 7 days, at which time the beads are removed and new modular parts inserted.
  • QUESTIONS/PURPOSES: We determined the ability of this two-stage débridement to control infection.
  • METHODS: We retrospectively reviewed the charts of 20 patients who underwent this technique; 2 had postoperative and 18 had hematogenous infections.
  • The primary outcome measure was the infection control.
  • RESULTS: Two of the 20 patients had persistent infection.
  • Of the 18 patients without evidence of persistent infection, 10 were no longer on antibiotics at the most recent followup and eight were treated with long-term antibiotics due to compromised host status.
  • CONCLUSIONS: The control of infection in 18 of 20 patients using this technique compares favorably with historical success rates, which range from 24% to 100%.
  • Further research is required to analyze the individual contribution of débridement technique, the use of serial débridements, local depot antibiotics, and combination antibiotic therapy on short-term infection control rates and the long-term persistent control of periprosthetic infection.
  • LEVEL OF EVIDENCE: Level IV, therapeutic study.
  • [MeSH-major] Anti-Bacterial Agents / therapeutic use. Bacterial Infections / therapy. Debridement. Joint Prosthesis / adverse effects. Prosthesis-Related Infections / therapy. Surgical Wound Infection / therapy
  • [MeSH-minor] Acute Disease. Adult. Aged. Aged, 80 and over. Arthroplasty, Replacement, Hip. Arthroplasty, Replacement, Knee. Bone Cements. Combined Modality Therapy. Drug Delivery Systems. Female. Hip Prosthesis / adverse effects. Hip Prosthesis / microbiology. Humans. Knee Prosthesis / adverse effects. Knee Prosthesis / microbiology. Male. Middle Aged. Reoperation. Retrospective Studies. Treatment Failure

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • MedlinePlus Health Information. consumer health - Bacterial Infections.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Bone Joint Surg Am. 1999 Oct;81(10):1434-45 [10535593.001]
  • [Cites] Clin Orthop Relat Res. 2008 Nov;466(11):2628-33 [18781372.001]
  • [Cites] Clin Orthop Relat Res. 2002 Oct;(403):23-8 [12360003.001]
  • [Cites] Clin Orthop Relat Res. 2002 Nov;(404):125-31 [12439250.001]
  • [Cites] Clin Infect Dis. 2003 Apr 1;36(7):845-9 [12652384.001]
  • [Cites] J Arthroplasty. 2003 Oct;18(7 Suppl 1):22-6 [14560406.001]
  • [Cites] J Bone Joint Surg Am. 1974 Mar;56(2):273-84 [4452686.001]
  • [Cites] Clin Orthop Relat Res. 1976 Jun;(117):221-40 [776484.001]
  • [Cites] J Arthroplasty. 1990 Mar;5(1):35-9 [2319246.001]
  • [Cites] J Bone Joint Surg Am. 1990 Oct;72(9):1383-90 [2229118.001]
  • [Cites] Clin Orthop Relat Res. 1991 Dec;(273):105-12 [1959256.001]
  • [Cites] Clin Orthop Relat Res. 1991 Dec;(273):113-8 [1959257.001]
  • [Cites] Clin Orthop Relat Res. 1991 Dec;(273):98-104 [1959294.001]
  • [Cites] Clin Orthop Relat Res. 1992 May;(278):244-52 [1563160.001]
  • [Cites] J Bone Joint Surg Am. 1996 Apr;78(4):512-23 [8609130.001]
  • [Cites] Clin Orthop Relat Res. 1996 Oct;(331):146-50 [8895631.001]
  • [Cites] J Arthroplasty. 1996 Dec;11(8):931-8 [8986571.001]
  • [Cites] J Arthroplasty. 1997 Jun;12(4):426-33 [9195319.001]
  • [Cites] JAMA. 1998 May 20;279(19):1537-41 [9605897.001]
  • [Cites] J Bone Joint Surg Am. 1998 Sep;80(9):1306-13 [9759815.001]
  • [Cites] Am J Orthop (Belle Mead NJ). 1999 Mar;28(3):161-5 [10195839.001]
  • [Cites] J Bone Joint Surg Am. 1999 May;81(5):672-83 [10360695.001]
  • [Cites] Arthroscopy. 2005 Mar;21(3):303-6 [15756183.001]
  • [Cites] J Bone Joint Surg Am. 2005 Jul;87(7):1415-22 [15995106.001]
  • [Cites] Clin Microbiol Infect. 2006 May;12(5):433-9 [16643519.001]
  • [Cites] Clin Orthop Relat Res. 2007 Aug;461:130-5 [17438469.001]
  • [Cites] J Bone Joint Surg Am. 2008 Aug;90(8):1637-43 [18676892.001]
  • [Cites] Clin Orthop Relat Res. 2002 Oct;(403):8-15 [12360001.001]
  • (PMID = 20224958.001).
  • [ISSN] 1528-1132
  • [Journal-full-title] Clinical orthopaedics and related research
  • [ISO-abbreviation] Clin. Orthop. Relat. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Bone Cements
  • [Other-IDs] NLM/ PMC2895840
  •  go-up   go-down


21. Sunamura M, Egawa S, Fukuyama S, Motoi F, Takeda K, Akada M, Ottomo S, Abe H, Matsuno S: [Chemotherapy for pancreatic cancer]. Gan To Kagaku Ryoho; 2003 Nov;30(12):1901-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Chemotherapy for pancreatic cancer].
  • Gemcitabine (GEM) has replaced 5-fluorouracil (5-FU)-based chemotherapy as the standard of care.
  • For locally advanced disease, most recent studies have incorporated GEM into combined-modality therapy.
  • Similarly, in surgically resectable disease, current trials are incorporating GEM into adjuvant therapy.
  • According to several clinical trials it has been demonstrated that improvements in locoregional control and survival may be achieved when chemotherapy using 5-FU is added to radiation for locally advanced pancreatic cancer.
  • The new regimen for locally advanced disease has demonstrated that the better outcome is expected by chemoradiation therapy with 5-FU followed by GEM treatment.
  • In order to develop chemotherapy for pancreatic cancer, we are analyzing mRNA expression of pancreas cancer cell lines and examined their resistant against to GEM.
  • One of the genes is demonstrated to be a responsible for drug sensitivity by clustering analysis.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Deoxycytidine / analogs & derivatives. Deoxycytidine / therapeutic use. Pancreatic Neoplasms / drug therapy
  • [MeSH-minor] Combined Modality Therapy. Humans. Pancreatectomy. Prognosis. Radiotherapy Dosage. Survival Rate

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14650957.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  • [Number-of-references] 31
  •  go-up   go-down


22. El Helou OC, Berbari EF, Lahr BD, Eckel-Passow JE, Razonable RR, Sia IG, Virk A, Walker RC, Steckelberg JM, Wilson WR, Hanssen AD, Osmon DR: Efficacy and safety of rifampin containing regimen for staphylococcal prosthetic joint infections treated with debridement and retention. Eur J Clin Microbiol Infect Dis; 2010 Aug;29(8):961-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy and safety of rifampin containing regimen for staphylococcal prosthetic joint infections treated with debridement and retention.
  • The aim of this study was to evaluate the efficacy and safety of rifampin for Staphylococcus aureus (SA) or coagulase negative staphylococci (CNS) prosthetic joint infection (PJI) treated with debridement and retention (D/R).
  • We calculated the treatment failure cumulative incidence (TF) of a cohort of 101 patients with SA or CNS PJI treated with D/R and antimicrobial therapy.
  • Cox proportional hazards regression evaluated the association between treatment and time-to-TF controlling for the propensity to treat with rifampin and temporal confounders.
  • Seven percent (1/14) of the prospective rifampin-treated patients, 32% (10/31) of the historical rifampin-treated patients and 38% (21/56) of the historical non-rifampin treated patients developed TF.
  • None (0/14) of the patients in the prospective study developed hepatotoxicity.
  • The outcome of staphylococcal PJI treated with D/R and rifampin-based regimens was better when compared with a historical cohort treated without rifampin.
  • [MeSH-major] Anti-Bacterial Agents / administration & dosage. Prosthesis-Related Infections / drug therapy. Rifampin / administration & dosage. Staphylococcal Infections / drug therapy. Staphylococcus / isolation & purification
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cohort Studies. Debridement. Female. Humans. Liver / drug effects. Male. Middle Aged. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • MedlinePlus Health Information. consumer health - Staphylococcal Infections.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RIFAMPIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Infect Dis. 2007 Nov 1;45(9):1113-9 [17918072.001]
  • [Cites] Sci Am. 1981 Oct;245(4):54-63 [7027437.001]
  • [Cites] Clin Infect Dis. 2006 Jan 15;42(2):216-23 [16355332.001]
  • [Cites] Clin Microbiol Infect. 2006 Sep;12(9):930-3 [16882303.001]
  • [Cites] Infection. 2004 Aug;32(4):222-8 [15293078.001]
  • [Cites] Clin Microbiol Infect. 2006 May;12 Suppl 3:93-101 [16669932.001]
  • [Cites] J Bone Joint Surg Am. 2007 Mar;89(3):526-33 [17332101.001]
  • [Cites] Clin Microbiol Infect. 2007 Jun;13(6):586-91 [17331125.001]
  • [Cites] Antimicrob Agents Chemother. 2006 Dec;50(12):4011-7 [17015630.001]
  • [Cites] Orthopedics. 1991 Aug;14(8):841-4 [1923965.001]
  • [Cites] Injury. 2006 May;37 Suppl 2:S3-14 [16651069.001]
  • [Cites] J Antimicrob Chemother. 2001 Aug;48(2):253-8 [11481297.001]
  • [Cites] J Antimicrob Chemother. 1997 Feb;39(2):235-40 [9069545.001]
  • [Cites] Lancet. 2001 Jul 14;358(9276):135-8 [11463434.001]
  • [Cites] Clin Infect Dis. 2006 Feb 15;42(4):471-8 [16421790.001]
  • [Cites] J Bone Joint Surg Am. 1998 Sep;80(9):1306-13 [9759815.001]
  • [Cites] JAMA. 1998 May 20;279(19):1537-41 [9605897.001]
  • [Cites] Clin Infect Dis. 2001 Feb 1;32(3):419-30 [11170950.001]
  • [Cites] Acta Orthop. 2007 Dec;78(6):755-65 [18236181.001]
  • [Cites] Am J Med. 2006 Nov;119(11):993.e7-10 [17071171.001]
  • [Cites] Clin Infect Dis. 2004 Nov 1;39(9):1285-92 [15494904.001]
  • [Cites] Mater Manag Health Care. 2006 Jul;15(7):61-2 [16900875.001]
  • (PMID = 20505968.001).
  • [ISSN] 1435-4373
  • [Journal-full-title] European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology
  • [ISO-abbreviation] Eur. J. Clin. Microbiol. Infect. Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; VJT6J7R4TR / Rifampin
  •  go-up   go-down






Advertisement